Allergy Therapeutics Share Price (AGY)

29.75 0.00 (0.00%) delayed: 6:56AM GMT
Bid price 29.00 Open price 29.89
Ask price 30.50 Prev close 29.75
High price 29.89 Spread 4.92%
Low price 29.20 Volume 30,630

Register now for FREE live Allergy Therapeutics share prices, Allergy Therapeutics stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Allergy Therapeutics Level 2 Data, indepth research tools and investor commentary for Allergy Therapeutics (AGY) and other London Stock Exchange equities.

Allergy Therapeutics Share Price Chart

Advanced Charts >>

Register now for FREE Allergy Therapeutics share price charts

Allergy Therapeutics Share Price Information

Name Allergy Therapeutics Epic AGY
Sector Pharmaceuticals & Biotechnology ISIN GB00B02LCQ05
Activites Allergy Therapeutics plc is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development. Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK. Index n/a

Allergy Therapeutics Key Numbers

Latest Share Price (p) 29.75 Net Gearing (%) 8.91
Market Capitalisation (£m) 176.75 Gross Gearing (%) 47.60
Shares in issue (m) 594.12 Debt Ratio 30.58
P/E Ratio -70.83 Debt-to-Equity Ratio 0.49
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.91
Dividend Yield (%) 0.00 Price to book value 5.90
Dividend cover (x) 0.00 ROCE (%) -4.56
Earning per share (p) -0.42 EPS Growth (%) 81.66
52 week high / low 39.50 / 23.00 DPS Growth (%) n/a

Allergy Therapeutics Director Deals

Dec.Date Type Director Pos No. of Shares
12/10/2017 BUY Dr Tunde Otulana NED 25,000
29/09/2016 BUY Peter Jensen CH 30,000
28/09/2016 BUY Nick Wykeman FD 150,000
26/09/2016 BUY Manuel Llobet CEO 100,000
27/07/2015 BUY Manuel Llobet CEO 50,000

More Allergy Therapeutics Director Deals >>

Allergy Therapeutics Company News

15:19 10/01/2018

Holdings in Company

RNS Number : 5221B Allergy Therapeutics PLC 10 January 2018   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i...

07:23 09/01/2018

Allergy Therapeutics completes recruitment for clinical study

Allergy Therapeutics said recruitment of the group's phase III clinical trial with PQ Birch (PQBirch301) has been completed as expected. The PQBirch301 study is designed to evaluate the safety and efficacy of the group's ultra-short course, convenient for patients, aluminium free PQ Birch...

07:00 09/01/2018

PQ Birch Phase III trial completes recruitment

RNS Number : 2889B Allergy Therapeutics PLC 09 January 2018         Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group")   PQ Birch Phase III clinical trial completes recruitment   9 January 2018 Allergy Therapeutics plc (AIM:AGY),...

More Allergy Therapeutics Company News >>

Register now for FREE Allergy Therapeutics company news

Allergy Therapeutics Share Price Discussions

10 days ago

Allergy Therapeutics PLC (AGY)

Mission Statement To create a sustainable, fast-growing and profitable global speciality pharmaceutical business with a substantial franchise in the allergy sector by developing innovative, patented, registered therapies for both the treatment and prevention of allergy-related conditions....

more than 1 year ago

Allergy TV Clip re: Successful Phase II Study (AGY)

more than 1 year ago

Allergy Therapeutics (AGY)

Good morning, Below is a short TV interview with Manuel & Ian covering today's interim results.

Register now for FREE Allergy Therapeutics share price discussions